iX Biopharma: FY15 net loss widened to $10.6m from FY14’s net loss of $3m despite a more than 5.7x jump in revenue to $7.4m driven by a 7.8x jump in chemical analysis revenue to $7.3m. However, revenue gains were wiped out by a 272% leap in R&D costs to $3.7m, a 342% jump in employee compensation, a net FX loss of $1.1m (FY14: $112k gain) as well as a one-off IPO expense of $1.4m. NAV/share of $0.02.
No comments:
Post a Comment